VAG
BIO icon

VisionPoint Advisory Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

VisionPoint Advisory Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$379 – 706
2023
Q2 		$379 Buy
+1
New +$407 ﹤0.01% 560

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VisionPoint Advisory Group's BIO Position: Q3 2023 in Review

VisionPoint Advisory Group sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 1 share — an estimated $379 sold.

VisionPoint Advisory Group first reported a position in BIO in Q2 2023 and held it in 1 quarter. The position peaked at $379 in Q2 2023. 467 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

  • VisionPoint Advisory Group reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
  • VisionPoint Advisory Group sold 1 Bio-Rad Laboratories Class A share in Q3 2023, an estimated $379.
  • VisionPoint Advisory Group first reported a position in Bio-Rad Laboratories Class A in Q2 2023 and held it in 1 quarter.
  • VisionPoint Advisory Group's Bio-Rad Laboratories Class A position peaked at $379 in Q2 2023.
  • 467 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on VisionPoint Advisory Group's 13F filing for Q3 2023, filed 6 Dec 2023.